• 1
    Eke T, Talbot J, Lawden MC, Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:1801.
  • 2
    Faeda MT, Giallonardo AT, Marchetti A, Manfredi M., Vigabatrin therapy for resistant partial epilepsies. Neuropsicofarmace 1993;15:1058.
  • 3
    Harding GFA, Severe persistent visual field constriction associated with vigabatrin: four possible mechanisms exist. BMJ 1997;314:1694.
  • 4
    Krauss GL, Johnson MA, Miller NR, Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:8149.
  • 5
    Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC, Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999;52:12015.
  • 6
    Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zakon D., Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999;106:17928.
  • 7
    Kalvianien R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field constriction. Neurology 1999;53:9226.
  • 8
    Lawden MC, Eke T, Degg C, Harding GFA, Wild JM, Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999;67:71622.
  • 9
    Wild JM, Martinez C, Reinshagen G, Harding GFA, Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;40:178494.
  • 10
    Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiological findings. Neurology 1999;53:20827.
  • 11
    Riekkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkanen A., Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmacol 1989;27:87S94.
  • 12
    Browne TR, Mattson RH, Penry JK, et al. A multicentre study of vigabatrin for drug resistant epilepsy. Br J Clin Pharmacol 1989;27(suppl):95S100.
  • 13
    Ben-Menachem E, Persson LI, Schecter PJ, et al. The effect of different vigabatrin treatment regimes on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27(suppl):79S85.
  • 14
    Michelucci R, Tassinari CA, Response to vigabatrin in relation to seizure type. Br J Clin Pharmacol 1989;27(suppl):119S124.
  • 15
    Kalvianien R, Akia M, Saukkonen AM, Mervaala E, Riekkinen P., Vigabatrin vs carbamazepine in patients with newly diagnosed epilepsy. Arch Neurol 1995;52:98996.
  • 16
    Graham D., Neuropathology of vigabatrin. Br J Clin Pharmacol 1989;27(suppl):43S5.
  • 17
    Cannon DJ, Butler WH, Mumford JP, Lewis PJ, Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991;(suppl 2):S1724.
  • 18
    Hammond EJ, Rangel RJ, Wilder BJ, Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 1989;61:1623.
  • 19
    Cosi V, Callieco R, Galimberti CA, et al. Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27:61S68.
  • 20
    Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P., Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients. Epilepsia 1989;30(suppl):S235.
  • 21
    Harding GFA, Jones LA, Tipper VJ, Betts TA, Mumford JP, Electroretinogram, pattern electroretinogram and visual evoked potential assessment in patients receiving vigabatrin. Epilepsia 1995;36(suppl):S108.
  • 22
    Mauguière F, Chauvel P, Dewailly J, Dousse N., No effect of long-term vigabatrin treatment on CNS conduction in epileptic patients: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997;38:3018.
  • 23
    Celesia GG, Bodis-Wollner I, Harding GFA, Sokol S, Sperkreijse H., Recommended standards for electroretinograms and visual evoked potentials: report of an IFCN committee. Electroencephalogr Clin Neurophysiol 1993;87:42136.
  • 24
    Harding GFA, Odom JV, Spileers W, Spekreijse H., Standard for visual evoked potentials. Vision Res 1995;36:216.
  • 25
    Marmor MF, Holder GE, Porciatti V, Trick GL, Zrenner E., Guidelines for basic pattern electroretinography. Doc Ophthalmol 1996;91:2918.
  • 26
    Arden GB, Barrada A., Analysis of the electro-oculograms of a series of normal subjects: role of the lens in the development of the standing potential. Br J Ophthalmol 1962;46:46882.
  • 27
    Sutter EE, Tran D., The field topography of ERG components in man. I. The photopic luminance response. Vision Res 1992;32:43346.
  • 28
    Harding GFA, Robertson KA, Edson AS, Barnes P, Wild JM, Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol 1999;97:17988.
  • 29
    Duckett T, Brigell MG, Ruckh S., Electroretinographic changes are not associated with loss of visual function in paediatric patients following treatment with vigabatrin. Invest Ophthalmol Vis Sci 1998;39(suppl):S973.
  • 30
    Falk G., Retinal physiology. In: HeckenlivelyJR, ArdenGB, eds. Principles & practice of clinical electrophysiology of vision. St. Louis : Mosby Year Book, 1991:6984.
  • 31
    Yang XL, Wu SM, Effects of GABA on horizontal cells in the tiger salamander retina. Vision Res 1993;33:133944.
  • 32
    Frumkes TE, Nelson R., Functional role of GABA in cat retina. I. Effects of GABA agonists. Vision Neurosci 1995;12:64150.
  • 33
    Cubells JF, Blanchard JS, Smith DM, Madman MH, Vivoaction of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs brain. J Pharmacol Exp Ther 1986;23:50814.
  • 34
    Neal MJ, Cunningham JR, Shah MA, Yazalla S., Immunocyto-chemical evidence that vigabatrin in rats cause GABA accumulation in glial cells of the retina. Neurosci Lett 1988;98:2932.